Silence Therapeutics PLC January Conference Schedule (5205K)
January 05 2021 - 1:00AM
UK Regulatory
TIDMSLN
RNS Number : 5205K
Silence Therapeutics PLC
05 January 2021
Silence Therapeutics to Participate in January Virtual U.S.
Investor Conferences
5 January 2021
LONDON, Silence Therapeutics plc , AIM: SLN and Nasdaq: SLN ("
Silence " or " the Company "), a leader in the discovery,
development and delivery of novel short interfering ribonucleic
acid (siRNA) therapeutics for the treatment of diseases with
significant unmet medical need, today announced that Company
management will participate in a fireside chat at two upcoming
investor conferences, details of which can be found below:
H.C. Wainwright BioConnect 2021 Conference
Date: January 11, 2021
Time: 6:00 a.m. EST (13:00 GMT)
ICR Conference 2021
Date: Thursday, January 14, 2021
Time: 8:30- 9:10 a.m. EST (13:30 - 14:10 GMT)
Live webcasts of the Company's presentations can be accessed via
the Investors section of the Company's website at
www.silence-therapeucs.com. An archived replay of the webcasts will
be available for 60 days on the Company's website following the
conference.
Enquiries:
Silence Therapeutics plc Tel: +1 (646) 637-3208
Gem Hopkins, Head of IR and Corporate Communications
ir@silence-therapeutics.com
Investec Bank plc (Nominated Adviser and Tel: +44 (0) 20
Broker) 7597 5970
Daniel Adams/Gary Clarence
European IR Tel: +44 (0) 20
Consilium Strategic Communications 3709 5700
Mary-Jane Elliott/ Angela Gray / Chris Welsh
silencetherapeutics@consilium-comms.com
U.S. IR Tel: +1 (443) 213-0505
Westwicke
Peter Vozzo
peter.vozzo@westwicke.com
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, to inhibit the expression of specific target genes thought to
play a role in the pathology of diseases with significant unmet
medical need. Silence's proprietary technology can be used to
engineer short interfering ribonucleic acids (siRNAs) that bind
specifically to and silence, through the RNAi pathway, almost any
gene in the human genome to which siRNA can be delivered. Silence's
wholly owned product candidates include SLN360 designed to address
the high and prevalent unmet medical need in reducing
cardiovascular risk in people born with high levels of
Lipoprotein(a) and SLN124 to address beta-thalassemia and
myelodysplastic syndrome. Silence is also developing SLN500, a C3
targeting program, in partnership with Mallinckrodt Pharmaceuticals
to reduce the expression of the C3 protein for the treatment of
complement pathway-mediated diseases. Silence maintains ongoing
research and collaborations with AstraZeneca, Mallinckrodt
Pharmaceuticals and Takeda. For more information, please visit:
https://www.silence-therapeutics.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDZGGMLDVGMZM
(END) Dow Jones Newswires
January 05, 2021 02:00 ET (07:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2023 to Apr 2024